Introduction
Materials and Methods
Tumor Specimens
BRAF V600E Immunohistochemistry
BRAF V600E Sanger Sequencing
Results
Anti-BRAF V600E (VE1) Immunohistochemistry
DNA Sequencing
# | Author | CRC Tissues | BRAF V600E Scoring Criteria | Notes from the publications on BRAF V600E scoring/staining |
---|---|---|---|---|
1 | Adackapara et al. [1] | 52 cases | Scoring criteria: negative, weak, moderate, strong, (any cytoplasmic staining even a blush scored as weak) | Moderate to strong cytoplasmic staining; relatively uniform staining throughout all positive cases, non-specific nuclear staining common. |
2 | Affolter et al. [2]. | 31 cases | Scoring criteria: based on the intensity of cytoplasmic staining, percentage of tumor cells stained | Staining in the majority of BRAF mutant cases was strong and diffuse. Semiquantitative analysis of stain intensity or percentage of staining cells was not useful, because most tumor cells stained in positive cases and staining was uniformly absent in negative cases. No indeterminate cases. Heterogeneous or weak staining occurred infrequently. Cilia, nuclei of colonocytes sometimes positive. |
3 | Bledsoe et al. [3] | 204 cases | Positive case: cytoplasmic staining, uniform to near uniform, intensity -weak to strong. | Pitfalls include signet-ring cell morphology. Dim but uniform staining should not be disregarded. Nuclear staining in normal cells. Nuclear staining occurred only in a minority of BRAF mutants, was regarded as nonspecific, and, in the absence of the cytoplasmic criteria, was taken as non-diagnostic. Nonspecific nuclear and heterogeneous, non-diffuse cytoplasmic staining of variable intensity was observed in occasional non–BRAF-mutant cases. |
Scoring criteria: negative, weak, moderate, strong. Diffuse or non-diffuse. Uniform (all malignant cells) or near uniform, heterogeneous (variable stain intensity). | ||||
4 | Capper et al. [7] | 91 cases | Positive case: staining of >80% tumor cells above background | Homogenous finely granular cytoplasmic staining was seen in most cases. No single anti-BRAF V600E (VE1) antibody positive cells or positive clonal foci in otherwise negative tumors were observed. |
5 | Day et al. [9] | 477 cases | Positive case: unequivocal cytoplasmic staining above background in the majority of invasive viable tumor cells. | Any nuclear staining, weak, cytoplasmic staining of isolated tumor cells or focal confluent staining of tumor cells in a tumor that otherwise showed no staining was scored as immune-negative. |
6 | Dvorak et al. [11] * | 279 cases | Positive case: diffuse cytoplasmic staining of >80% tumor cells | Heterogeneous staining in 3 cases out of 238 CRC on TMA |
7 | Kuan et al. [19] | 128 cases | Scoring criteria: 3+, 2+, 1+, 0 | Scoring assessment based on stain intensity is appropriate. Weak even diffuse staining (1+) is not diagnostic and requires testing by PCR analysis. |
8 | Lasota et al. [20] | 113 cases | Scoring criteria: negative, weak, moderately positive, strongly positive | 2 KRAS cases false positive, suboptimal protocol used |
9 | Loes et al. [21] | 99 cases | Scoring criteria: 0-no staining, 1-weak diffuse cytoplasmic staining, 2 moderate diffuse, granular cytoplasmic staining, 3- strong diffuse granular cytoplasmic staining; 0–1 negative, 2–3 positive | In positive samples the staining was homogeneous with equal intensity throughout the majority of tumor cells. |
10 | Rossle et al. [33] | 68 cases | Scoring criteria: 0- negative, 1 weakly/moderately positive, 2 strongly positive. | Diffuse staining of variable intensity (from weak to strong) in most cases. False positive staining noted in signet ring tumor cells. |
Positive case: unequivocal cytoplasmic staining of a majority of tumor cells, | ||||
11 | Roth et al. [34] | 55 cases | Positive case: Uniform diffuse cytoplasmic staining (even week) in all tumor cells | Most cases –strong, diffuse, uniform cytoplasmic staining, a few cases showed weaker but diffuse and convincingly cytoplasmic staining |
12 | Sinicrope et al. [39] | 74 cases | Scoring criteria: 0 none, 1+ weak, 2+ medium, 3+ strong) | Homogenous staining seen in the majority of cases. Any nuclear staining or weak interspersed staining was scored as negative. Any nuclear staining or weak staining of interspersed cells was scored as negative. BRAF V600E expression was homogeneous. 100% of tumor cells stained in 75% cases, >70% cells stained in all cases. |
Positive case: at least 70% tumor cells stained | ||||
13 | Toon et al. [43] | 201 cases | Positive case: diffuse strong positive staining of >75% of malignant cells | The great majority of positive cases actually demonstrated diffuse strong homogenous cytoplasmic staining in essentially all malignant cells, whereas the great majority of negative cases showed completely absent staining in all malignant cells. Patchy non-specific staining in smooth muscle cells, mucin, and colonic mucosa (with nuclear staining). Weak but diffuse staining seen occasionally in positive cases. |
14 | Piton et al. [28] | 30 cases | Positive case: >10% tumor cells showed positive signal.. | BRAF mutants – staining homogeneous, cytoplasmic, finely granular. Any nuclear staining was ignored and not scored. |
15 | Qui et al. [29]* | 181 cases | Cytoplasmic staining | The interpretation of the results was clear. The negative and positive samples can be easily distinguished without the need of a subjective IHC scoring system based on stain intensity or percentage of positively stained cells. |
16 | Thiel et al. [42] | 176 cases | Positive case: detectable granular cytoplasmic staining | No details |
17 | Hang et al. [13] | 425 cases | Scoring criteria: negative (0), weak (1+), moderate (2+), strong (3+) | 2 cases heterogeneous staining, 70% cells stained, 8/425 cases were called equivocal due to low stain intensity |
18 | Schafroth et al. [37] | 33 cases | Scoring criteria: cytoplasmic staining – weak to strong | Interpretation of weak staining is challenging. About 10% of cases – weak staining, these cases should be validated by another method. Nuclear staining sometimes observed in tumor cells- considered negative. Heterogeneity – minimal. |
19 | Estrella et al. [12] | 480 cases | Scoring criteria: 0-negative, 1- weak in <20% tumor cells, 2-moderate to strong in <20% tumor cells, 3 weak in 20–70% tumor cells, 4-moderate or strong in 20–70% tumor cells, 5 weak in >70% tumor cells, 6 moderate to strong in >70% tumor cells. | Scoring system was completely different than other studies. |
20 | Vakiani et al. [45] | 117 cases | Scoring criteria: Weak, moderate, strong. | In majority of the cases, positive/negative score- readily achieved. Equivocal - 4 cases, 3 cases- nuclear staining in tumor cells, 1 case focal nuclear and weak cytoplasmic, mucinous carcinoma, or signet ring. |
Positive case: >80% cell tumor staining above any background staining, | ||||
Equivocal case: nuclear staining with cytoplasmic staining in tumor cells. | ||||
21 | Boulagnon et al. [4] | 86 cases | Positive cases: (cytoplasmic, diffuse, moderate to intense), Negative cases: no or faint cytoplasmic staining | Only 3 cases equivocal because of heterogeneous staining pattern |
Equivocal case: heterogeneous, or weak staining | ||||
22 | Sajanti et al. [36] | 147 cases | Positive case: diffuse staining in the tumor cells | All BRAF mutated CRCs showed diffuse and strong staining |
23 | Routhier et al. [35] | 25 cases | Positive case: diffuse and moderate to strong cytoplasmic staining of tumor cell. | No details. |
Negative case: isolated nuclear staining, weak staining of occasional cells or faint diffuse staining – | ||||
24 | Nolan et al. [24] | 152 cases | Positive case: diffuse cytoplasmic staining of >80% tumor cells, ranging from medium to strong in strength. | This study included also equivocal category – PCR confirmatory test needed for these cases. Only 8 equivocal cases. |
Negative case: absent staining or very weak staining of similar intensity to the control normal mucosa, | ||||
Equivocal case: heterogeneous staining | ||||
25 | Ilie et al. [16] | 489 cases | Positive case: >80% cell tumor staining, strong, distinct, homogeneous staining | Equivocal cases –additional analysis required for such cases |
Equivocal case: ambiguous, focal, moderate staining |
Disscussion
First author | Molecular testing | Tissue source | Instrument/ Detection | Sensitivity %(n/N) | Specificity %(n/N) | Antibody/dilution | Antigen retrieval /antibody incubation | |
---|---|---|---|---|---|---|---|---|
1 | Adackapara et al. [1] | Pyrosequencing | WS | Manual/ Not specified | 71% (12/17) | 74% (26/35) | Spring 1:50 | Citrate buffer pH 6/overnight 4 °C |
2 | Affolter et al. [2]. | Pyrosequencing | WS | BMK ULTRA/ ultraView Amplification | 100% (14/14) | 100% (17/17) | Spring 1:600 | Manual AR/60 min antibody |
3 | Bledsoe et al. [3] | Multiplex PCR, SNaPshot | TMA, WS | Leica/Bond-III | 96% (57/59) | 99% (143/145) | Spring 1:100 | 40 min EDTA buffer pH 9 / Not specified |
4 | Capper et al. [7] | Sanger and pyrosequencing | WS | BMK XT/ OptiView Amp | 100% (11/11) | 99% (79/80) | Hybridoma 1:5 | 64 min CC1/32 min antibody |
5 | Day et al. [9] | Sanger and SNaPShot | TMA, WS | BMK XT/OptiView, ultraView | 100% (59/59) | 100% (416/416) | Hybridoma 1:3 | 64 min CC1/16 min antibody |
6 | Dvorak et al. [11] * ++ | Sanger, SNapShot, and NGS | TMA, WS | BMK XT/ OptiView | 100% (86/86) | 99% (191/193) | Ventana 1:50 | 64 min CC1/16 min antibody |
7 | Kuan et al. [19] | PCR | WS | BMK ULTRA/OptiView | 100% (74/74) | 94% (51/54) | Spring 1:200 | 56 min CC1/20 min antibody |
8 | Lasota et al. [20]** | Multiple analyses, Cobas | WS | Leica/ Bond-Max/Polymer detection | 89% (24/27) | 78% (64/86) | Spring 1:200 | 25 min Bond Epitope retrieval solution 1/30 min antibody |
9 | Loes et al. [21]* | Sanger and LightMix | TMA | BMK XT/OptiView | 59%(13/22) | 84% (63/75) | Spring 1:60 | 64 min CC1/16 min antibody |
10 | Rossle et al. [33] | Sanger and ultra-deep sequencing | WS | BMK XT/OptiView | 100% (37/37) | 95% (20/21) | Spring 1:200 | 64 min CC1/32 min antibody |
11 | Roth et al. [34] | Multiplex PCR | TMA, WS | Leica Bond/ Not specified | 88% (28/32) | 100% (23/23) | Spring 1:900 | 20 min Leica Bond EDTA solution pH 9/15 min antibody |
12 | Sinicrope et al. [39] | Multiplex PCR | WS | BMK XT/OptiView | 100% (49/49) | 100% (25/25) | Spring 1:45 | Not specified/16 min antibody |
13 | Toon et al. [43] | Multiplex PCR, MS | WS | Not specified | 97% (37/38) | 96% (157/163) | Hybridoma/Not specified | Not specified/ Not specified |
14 | Piton et al. [28] | SNapShot | WS | Manual/DAKO EnVision | 100% (10/10) | 100% (20/20) | Spring Not specified | 30 min citrate buffer pH 6/16 min antibody |
15 | Qui et al. [29]* ++ | Sanger, RT-PCR, Cobas | WS | BMK not specified/OptiView | 100% (38/38) | 100% (143/143) | Ventana 1:50 | 64 min CC1/16 min antibody |
16 | Thiel et al. [42] | PCR | TMA | BMK XT/OptiView or ultraView with/ without Amp | 100% (26/26) | 100% (129/129) | Spring 1:2000 | Not specified/ Not specified |
17 | Hang et al. [13] | PCR | TMA | Leica Bond-Max /Bond Polymer Refine detection | 91% (21/23) | 99% (397/402) | Spring 1:200 | 30 min Bond Epitope retrieval solution 2 /15 min antibody |
18 | Schafroth et al. [37] | Pyrosequencing | TMA, WT | BMK ULTRA/ OptiView | 100% (18/18) | 93% (14/15) | Ventana 1:50 | 72 min CC1/40 min antibody |
19 | Estrella et al. [12] | Different methods | WT | Leica Bond/Bond Polymer Refine detection | 75% (106/142) | 93% (315/338) | Spring 1:50 | 20 min TRIS-EDATA buffer pH 9/Not specified |
BMK ULTRA/ OptiView | 89% (51/57) | 57% (20/35) | 64 min CC1/ Not specified | |||||
20 | Vakiani et al. [45] | PCR, Sanger | WT | BMK XT/OptiView | 94% (45/48) | 96% (66/69) | Spring 1:50 | 32 min AR/32 min antibody |
21 | Boulagnon et al. [4] | RT-PCR | TMA, WT | BMK XT/ ultraView | 95% (20/21) TMA 100% (21/21) WT | 92% (60/65) TMA 95% (62/65) WT | Abcys EuroBio 1:50 | 64 min CC1/32 min antibody |
22 | Sajanti et al. [36] | PCR | TMA | BMK XT/ OptiView Ampl | 100% (13/13) | 99% (133/134) | Spring 1:2000 | Not specified/ Not specified |
23 | Routhier et al. [35] | SNapShot | WT | Leica Bond 3/Leica Polymer Refine detection | 100% (17/17) | 100% (15/15) | Spring 1:100 | 40 min EDTA solution (Leica) /Not specified |
24 | Nolan et al. [24] | PCR | WT | BMK ULTRA/ ultraView Ampl | 93% (14/15) | 100% (59/59) | Spring Not specified | 32 min CC1/32 min antibody |
25 | Ilie et al. [16] | Sanger, pyrosequencing | WT | BMK XT/OptiView | 94.2% (32/34) | 100% (276/276) | Spring 1:50 | Not specified/ Not specified |